Immunotherapeutic Effects of Allogeneic Mesenchymal Stem Cells on Systemic Lupus Erythematosus

The study explored the use of allogeneic mesenchymal stem cells (MSCs) to treat systemic lupus erythematosus (SLE) in MRL/lpr mice. MSCs from green fluorescent protein-transgenic ICR mice were administered at various disease stages, with dosages ranging from one to five doses at 2-week intervals. It was found that early treatment with two doses of MSCs significantly alleviated SLE symptoms, including hair loss, skin ulcers, proteinuria, and anti-dsDNA levels, more effectively than both lower and higher doses. The study concluded that early intervention with an optimal MSC dose effectively suppressed SLE in the murine model.